Abstract Details

Title The Efficacy of Pregabalin in Patients with Moderate and Severe Pain Due to Diabetic Peripheral Neuropathy

Topic Peripheral Nerve

Presentation(s) P01 - (-)

Poster/Presentation
Number 123

Objective

Background BACKGROUND: Severity of neuropathic pain due to DPN is correlated with negative health impact and increased healthcare utilization. Pregabalin is approved for treatment of DPN and this study examines its efficacy in patients with moderate and severe levels of pain.

Design/Methods DESIGN/METHODS: Data were pooled from 11 placebo-controlled trials of pregabalin for the treatment of DPN (placebo n=1047; pregabalin n=2028). Treatment arms included 150-, 300- and 600 mg/day doses. Pain scores were based on an 11-point numeric rating scale (0-10), and scores of ?4 to <7 and ?7 to ?10 were classified as moderate and severe, respectively. Pregabalin-mediated changes in pain, pain-related sleep interference (PSRI), and patient global impression of change (PGIC) were first compared versus placebo, and then between moderate and severe pain groups.

Results RESULTS: Pregabalin significantly reduced pain scores from baseline to endpoint compared to placebo (all doses p<0.05) when patients of all pain levels were combined. Both 300- and 600 mg/day pregabalin significantly improved pain scores at endpoint, compared to placebo, in patients with moderate or severe levels of pain (p<0.001). Improvements over placebo were of a greater magnitude in patients with severe baseline pain (300 mg/day = -0.91; 600 mg/day = -1.37) compared to those with moderate pain (300 mg/day = -0.48; 600 mg/day = -0.65). Pregabalin also improved PRSI and PGIC in the moderate and severe groups compared to placebo, with greatest improvement occurring in the severe group.

Conclusions CONCLUSIONS: Pregabalin was effective in DPN patients with both moderate and severe levels of pain. Patients with severe pain exhibited greater improvements in pain, PRSI and PGIC than patients with moderate pain, suggesting that pain severity may, in part, predict therapeutic response to pregabalin.

Authors/Disclosures
Birol Emir, PhD (Pfizer) PRESENTER	No disclosure on file
B. Parsons	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��